Key facts
- Novartis India has launched Pluvicto, a precision radiotherapy for prostate cancer.
- Pluvicto is the first approved radioligand therapy in India for PSMA-positive prostate cancer.
- The treatment targets prostate cancer cells while minimizing damage to healthy tissues.
- The therapy aims to provide a new treatment approach for metastatic prostate cancer.
Novartis India has launched Pluvicto, a precision radiotherapy for prostate cancer. The therapy is the first in India to receive regulatory approval for eligible patients with PSMA-positive prostate cancer. Pluvicto is designed to precisely target cancer cells while minimizing exposure to healthy tissues, offering a new treatment approach for metastatic prostate cancer. Judith Love, Novartis Region Head Asia Pacific, Middle East Africa, highlighted India as a priority market for Novartis, emphasizing the growing momentum in precision oncology and advanced cancer care. Amitabh Dube, Novartis India Country President and Managing Director, stated that Pluvicto will be made available through select hospitals and nuclear medicine centers across India as part of Novartis' partnership-led approach for radioligand therapies.